Tech Company Financing Transactions
T-Therapeutics Funding Round
On 11/17/2025, T-Therapeutics announced $32 million in Series A financing from BGF Ventures, Cambridge Innovation Capital and Digitalis Ventures.
Transaction Overview
Company Name
Announced On
11/17/2025
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to drive its pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic, including the further exploration of new therapeutic strategies such as T cell subset depletion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Suite 1 Riverside 3 Granta Park
Cambridge, England, CB21 6AD
UK
Cambridge, England, CB21 6AD
UK
Phone
Undisclosed
Website
Email Address
Overview
T-Therapeutics is developing a pipeline of first-in-class drugs that will become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Allan Bradley
Chief Financial Officer
Alison Lloyd
Browse more venture capital transactions:
Prev: 11/17/2025: TearOptix venture capital transaction
Next: 11/17/2025: Gridware venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs